Sanofi-aventis Patient Assistance Program
Sanofi-aventis, makers of Rilutek® (riluzole) tablets, is committed to helping patients
with ALS and their caregivers, and provides them with 2 patient assistance programs:
The Rilutek Continuity Program
- 1-800-RILUTEK
- Provides ALS patients with the following free services:
- Complete pharmacy services.
- Assistance with insurance forms and claims, including job loss
or change.
- Electronic claims processing where permitted by the plan.
- Advocacy if claim is delayed, denied, or sent to a case manager.
- Assistance with accessing federal and state payment programs.
- Referral to the Rilutek Patient Assistance Program.
The Rilutek Patient Assistance Program
- Provides an equal opportunity for ALS patients to receive treatment
- Has helped to cover the cost of Rilutek for hundreds of eligible
patients
- The program is sponsored by sanofi-aventis and is administered
by the National Organization for Rare Disorders (NORD)
- Eligibility is determined solely by medical and financial criteria.
All eligibility decisions are made by NORD
Logon to www.sanofi-aventis.com for
more information about the company’s creativity and innovation in patient health.
 |
 |
 |
|
|
Important Treatment Considerations
- Evaluate serum ALT levels every month during the first 3 months
of treatment, and every 3 months during the remainder of the first year. Thereafter,
serum ALT levels should be periodically evaluated more frequently in patients who
develop elevations. Rilutek should be discontinued if ALT levels increase to 5 times
ULN or if clinical jaundice develops.
- Advise patients about the potential for dizziness, vertigo, or
somnolence and not to drive or operate machinery until they have sufficient experience
on Rilutek.
- Advise patients to report any febrile illness; measure WBCs.
- Use Rilutek with caution in patients with concomitant liver insufficiency;
caution should be exercised when prescribing Rilutek to patients taking drugs that
are potentially hepatotoxic or highly protein bound:
- Interactions may also occur when riluzole is given concurrently
with agents that affect hepatic CYP 1A2 activity.*
|
|
|
 |
|
 |
|
|
|
|